Omeros Reports Final Efficacy and Safety Data from the Narsoplimab Pivotal Trial in HSCT-TMABusiness Wire • 10/22/20
Omeros Schedules Webcast to Present Final Efficacy Results from Narsoplimab BLA for the Treatment of HSCT-TMABusiness Wire • 10/15/20
Expert Panel Points to Central Role of Endothelial Injury and Lectin Pathway Activation in Critically Ill COVID-19 PatientsBusiness Wire • 09/03/20
Shares of Seattle biotech firm Omeros spike after reporting COVID-19 treatment resultsGeekWire • 08/11/20
Omeros Announces Proposed Public Offerings of Common Stock and Convertible Senior NotesBusiness Wire • 08/10/20
Omeros Corporation Reports Recovery and Survival of All Patients in Study Evaluating Narsoplimab for Treatment of COVID-19-Associated Acute Respiratory Distress SyndromeBusiness Wire • 08/10/20
Omeros Gets Technical Rating Upgrade, Relative Strength Line Moves Up To 75Investors Business Daily • 05/26/20
Omeros Corporation (OMER) CEO Greg Demopulos on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/12/20